90
Views
2
CrossRef citations to date
0
Altmetric
Review

Insulin glulisine in the management of diabetes

Pages 111-115 | Published online: 27 Sep 2022
 

Abstract

Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.

Disclosures

The author declares no conflicts of interest.